But the KOSTAIVE U.S. BLA filing is anticipated for later this year 2025. On the manufacturing front, Meiji Seika Pharma, our Japanese vaccine partner, submitted a manufacturing and marketing ...

A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

ORLANDO, Fla. — Dosing of the oral Janus kinase (JAK) inhibitor upadacitinib can be increased or decreased in adult patients with moderate to severe atopic dermatitis (AD) to achieve the desired ...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word (s): Personnel Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent Chairman ...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word (s): Annual Report Newron presents 2024 financial results and provides 2025 outlook 01.04.2025 / 07:00 CET/CEST The issuer is solely responsible ...

The big pharma is paying $66 million upfront for rights to tebipenem in all regions, except Japan and some other Asian countries – where rights are held by Meiji Seika – and will also make a $ ...

Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on developing novel therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso, ...

The interests from the past three years are as follows. MH received honoraria from Meiji Seika Pharma Co., Ltd. and Sumitomo Pharma Co., Ltd. TS received honoraria from Meiji Seika Pharma Co., Ltd.